Skip to content
Disclosery

AIHC Capital Management Ltd

Follow

13F filer, CIK 2103725, CENTRAL, Hong Kong

AIHC Capital Management Ltd reported $119,668,111 across 5 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-08.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001172661-26-001629

Period
2026-03-31
Reported value
$120M
Holdings
5
Top 10 weight
100%
New
1
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ORICnew+2,459,551$31.2M
NBPadded+1,848,954$4.55M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PTGXexited-189,823-$16.6M
AVBPexited-644,788-$13M
RVMDreduced-71,418-$6.95M
COGTreduced-48,598-$1.87M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001172661-26-001629, largest first. % of portfolio is the value over $119,668,111, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 900,392 shares; 2026Q1: 828,974 shares 828,974$80.6M67.37%-71,418Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 2,459,551 shares 2,459,551$31.2M26.04%newTimeline
NBPNOVABRIDGE BIOSCIENCESQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 413,979 shares; 2026Q1: 2,262,933 shares 2,262,933$5.57M4.65%+1,848,954Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 100,000 shares; 2026Q1: 51,402 shares 51,402$1.98M1.65%-48,598Timeline
KRROKORRO BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 30,265 shares; 2026Q1: 30,265 shares 30,265$343K0.29%0Timeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
PTGXPROTAGONIST THERAPEUTICS INC189,823$16.6Mshares
AVBPARRIVENT BIOPHARMA INC644,788$13Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001172661-26-001629 base2026-05-08acceptance time not in the bulk data set